Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01681992 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,538
- Enrollment target
NCT01681992 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,538 participants.
The verdict
NCT01681992, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,538 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
Interventions
- BIOLOGICAL Priorix
- BIOLOGICAL M-M-R II
- BIOLOGICAL Varivax
- BIOLOGICAL Havrix
- BIOLOGICAL Prevnar 13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,538 participants |
| Start Date | 2012-10-10 |
| Est. Completion | 2015-08-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01681992
The ClinicalTrials.gov registry entry for NCT01681992 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,538 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Priorix is the first listed.
NCT01681992 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01681992 about?
NCT01681992 is a clinical study titled "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life". The purpose of this study is to evaluate end of shelf-life potency in terms of the immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to Merck \& Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
What is the current status of trial NCT01681992?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,538 participants. The study started on 2012-10-10. Estimated completion is 2015-08-18.
What interventions are being tested in trial NCT01681992?
The interventions under investigation include: Priorix (BIOLOGICAL), M-M-R II (BIOLOGICAL), Varivax (BIOLOGICAL), Havrix (BIOLOGICAL), Prevnar 13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01681992?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.